Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

11.10 +0.01 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NextCure, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
From NextCure
Via GlobeNewswire
News headline image
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Year-End Clinical Pipeline Updates
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting 
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
News headline image
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
News headline image
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the JMP Securities Life Sciences Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at SVB Securities Global Biopharma Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at Upcoming Investor Conferences
From NextCure
Via GlobeNewswire
News headline image
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
From NextCure
Via GlobeNewswire
News headline image
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
From NextCure
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.